Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Sep-24 7:41 PM View:  | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 23-Sep-24 | Option Exercise | 9,772 | $52.72 | $515,227.00 | 19% 50.78K to 60.55K | |
| 24-Sep-24 7:41 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 23-Sep-24 | Option Sale | 9,377 | $101.22 | $949,139.00 | (15%) 60.55K to 51.17K | |
| 25-Sep-24 8:54 PM View: | Reardon Andrew CLO & Secretary | Ligand Pharmaceuticals Inc. (LGND) | 23-Sep-24 | Option Exercise | 2,000 | $52.27 | $104,540.00 | 9% 22.53K to 24.53K | |
| 24-Sep-24 7:41 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 23-Sep-24 | Sale | 395 | $101.22 | $39,981.80 | (< 1%) 51.17K to 50.78K | |
| 25-Sep-24 8:54 PM View: | Reardon Andrew CLO & Secretary | Ligand Pharmaceuticals Inc. (LGND) | 23-Sep-24 | Option Sale | 2,000 | $99.60 | $199,201.00 | (8%) 24.53K to 22.53K | |
| 24-Sep-24 7:41 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 20-Sep-24 | Option Sale | 5,377 | $104.10 | $559,755.00 | (9%) 57.05K to 51.67K | |
| 24-Sep-24 7:41 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 20-Sep-24 | Sale | 1,275 | $103.94 | $132,518.00 | (5%) 25.89K to 24.61K | |
| 24-Sep-24 7:41 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 20-Sep-24 | Option Exercise | 4,982 | $49.99 | $249,050.00 | 10% 52.07K to 57.05K | |
| 24-Sep-24 7:41 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 20-Sep-24 | Sale | 898 | $104.10 | $93,483.30 | (2%) 51.67K to 50.78K | |
| 19-Sep-24 5:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 17-Sep-24 | Option Exercise | 1,486 | $79.63 | $118,328.00 | 6% 24.4K to 25.89K | |
| 18-Sep-24 7:55 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 16-Sep-24 | Option Exercise | 5,774 | $58.49 | $337,696.00 | 12% 49.51K to 55.28K | |
| 18-Sep-24 7:55 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 16-Sep-24 | Payment of Exercise | 3,214 | $105.00 | $337,470.00 | (6%) 55.28K to 52.07K | |
| 30-Aug-24 8:56 PM View: | Reardon Andrew CLO & Secretary | Ligand Pharmaceuticals Inc. (LGND) | 28-Aug-24 | Option Sale | 1,500 | $106.39 | $159,591.00 | (6%) 24.03K to 22.53K | |
| 30-Aug-24 8:56 PM View: | Reardon Andrew CLO & Secretary | Ligand Pharmaceuticals Inc. (LGND) | 28-Aug-24 | Option Exercise | 1,500 | $52.27 | $78,405.00 | 7% 22.53K to 24.03K | |
| 30-Aug-24 9:00 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 28-Aug-24 | Option Exercise | 753 | $66.52 | $50,086.40 | 3% 23.65K to 24.4K | |
| 26-Aug-24 8:15 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 26-Aug-24 | Sale | 11,389 | $105.61 | $1,202,830.00 | (19%) 60.9K to 49.51K | |
| 26-Aug-24 8:15 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 23-Aug-24 | Sale | 6,312 | $104.80 | $661,479.00 | (9%) 67.21K to 60.9K | |
| 26-Aug-24 8:15 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 22-Aug-24 | Sale | 1,157 | $105.54 | $122,110.00 | (2%) 68.37K to 67.21K | |
| 13-Aug-24 5:21 PM View: | Korenberg Matthew E President & COO | Ligand Pharmaceuticals Inc. (LGND) | 09-Aug-24 | Sale | 18,245 | $98.50 | $1,797,130.00 | (21%) 86.61K to 68.37K | |
| 09-Aug-24 5:52 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 08-Aug-24 | Private Purchase | 2,500 | $97.39 | $243,480.00 | 2% 120.51K to 123.01K | |
| 02-Jul-24 7:44 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 28-Jun-24 | Acquisition (other) | 350 | $60.71 | $21,247.50 | < 1% 120.16K to 120.51K | |
| 02-Jul-24 7:45 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 28-Jun-24 | Acquisition (other) | 350 | $60.71 | $21,247.50 | < 1% 86.26K to 86.61K | |
| 02-Jul-24 7:45 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 28-Jun-24 | Acquisition (other) | 267 | $60.71 | $16,208.80 | 1% 23.38K to 23.65K | |
| 02-Jul-24 7:45 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 28-Jun-24 | Acquisition (other) | 329 | $60.71 | $19,972.60 | 1% 22.2K to 22.53K | |
| 25-Jun-24 7:45 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 14-Jun-24 | Grant | 1,252 | -- | -- | 4% 28.93K to 30.18K | |
| 17-May-24 7:59 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 17-May-24 | Option Exercise | 6,917 | $55.71 | $385,346.00 | 32% 21.62K to 28.54K | |
| 17-May-24 7:59 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 17-May-24 | Option Sale | 5,156 | $86.66 | $446,844.00 | (18%) 28.54K to 23.38K | |
| 17-May-24 7:59 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 16-May-24 | Sale | 2,058 | $86.00 | $176,995.00 | (9%) 23.68K to 21.62K | |
| 17-May-24 7:59 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 16-May-24 | Option Sale | 206 | $86.00 | $17,716.70 | (< 1%) 23.88K to 23.68K | |
| 17-May-24 7:59 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 15-May-24 | Sale | 5,873 | $86.01 | $505,148.00 | (20%) 29.75K to 23.88K | |
| 15-May-24 7:34 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 14-May-24 | Sale | 14,158 | $85.10 | $1,204,910.00 | (14%) 100.42K to 86.26K | |
| 15-May-24 7:34 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 13-May-24 | Sale | 3,440 | $84.54 | $290,828.00 | (3%) 103.86K to 100.42K | |
| 13-May-24 5:32 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 09-May-24 | Option Exercise | 10,000 | $52.27 | $522,700.00 | 45% 22.2K to 32.2K | |
| 13-May-24 5:32 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 09-May-24 | Option Sale | 10,000 | $83.04 | $830,449.00 | (31%) 32.2K to 22.2K | |
| 17-May-24 8:00 PM View: | Gray Nancy Ryan Director | Ligand Pharmaceuticals Inc. (LGND) | 09-May-24 | Sale | 934 | $83.20 | $77,713.40 | (14%) 6.57K to 5.63K | |
| 02-May-24 6:07 PM View: | Aryeh Jason Director | Ligand Pharmaceuticals Inc. (LGND) | 30-Apr-24 | Option Exercise | 2,406 | $52.30 | $125,834.00 | 2% 131.04K to 133.45K | |
| 26-Apr-24 6:35 PM View: | Kozarich John W Director | Ligand Pharmaceuticals Inc. (LGND) | 24-Apr-24 | Option Exercise | 2,893 | $39.35 | $113,840.00 | 7% 39.63K to 42.52K | |
| 27-Mar-24 5:47 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 25-Mar-24 | Option Exercise | 16,015 | $57.39 | $919,147.00 | 15% 104.14K to 120.16K | |
| 07-Mar-24 1:27 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 05-Mar-24 | Option Exercise | 2,893 | -- | -- | 10% 27.93K to 30.82K | |
| 07-Mar-24 1:27 PM View: | Sabba Stephen L Director | Ligand Pharmaceuticals Inc. (LGND) | 05-Mar-24 | Option Sale | 1,893 | $74.30 | $140,650.00 | (6%) 30.82K to 28.93K | |
| 06-Mar-24 10:00 PM View: | Aryeh Jason Director | Ligand Pharmaceuticals Inc. (LGND) | 05-Mar-24 | Option Exercise | 2,893 | $39.35 | $113,840.00 | 2% 128.15K to 131.04K | |
| 29-Feb-24 6:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 28-Feb-24 | Option Exercise | 1,264 | $56.62 | $71,564.30 | 4% 28.63K to 29.89K | |
| 29-Feb-24 6:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 28-Feb-24 | Option Sale | 140 | $88.46 | $12,384.40 | (< 1%) 29.89K to 29.75K | |
| 29-Feb-24 6:49 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 32,436 | -- | -- | 45% 71.71K to 104.14K | |
| 29-Feb-24 6:50 PM View: | Espinoza Octavio Chief Financial Officer | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 7,208 | -- | -- | 34% 21.42K to 28.63K | |
| 29-Feb-24 6:50 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 7,208 | -- | -- | 48% 15.0K to 22.2K | |
| 29-Feb-24 6:50 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 27-Feb-24 | Grant | 14,416 | -- | -- | 16% 89.44K to 103.86K | |
| 16-Feb-24 8:10 PM View: | Davis Todd C Chief Executive Officer Director | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 1,381 | $74.65 | $103,092.00 | (2%) 73.09K to 71.71K | |
| 16-Feb-24 8:10 PM View: | Korenberg Matthew E PRESIDENT & CHIEF OPERATING | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 4,778 | $74.65 | $356,678.00 | (5%) 94.22K to 89.44K | |
| 16-Feb-24 8:10 PM View: | Reardon Andrew CHIEF LEGAL OFFICER & | Ligand Pharmaceuticals Inc. (LGND) | 15-Feb-24 | Payment of Exercise | 593 | $74.65 | $44,267.40 | (4%) 15.59K to 15.0K |
